Your browser doesn't support javascript.
loading
Two Novel Biomarker Candidates for Differentiating Basal Cell Carcinoma from Trichoblastoma; Asprosin and Meteorine Like Peptide.
Kocaman, Nevin; Yuksel, Esma Inan; Demir, Betul; Calik, Ilknur; Cicek, Demet.
Affiliation
  • Kocaman N; Department of Histology and Embryology, Firat University School of Medicine, Elazig, Turkey. Electronic address: drnkocaman@gmail.com.
  • Yuksel EI; Department of Dermatology, Firat University School of Medicine, Elazig, Turkey.
  • Demir B; Department of Dermatology, Firat University School of Medicine, Elazig, Turkey.
  • Calik I; Department of Pathology, Firat University School of Medicine, Elazig, Turkey.
  • Cicek D; Department of Dermatology, Firat University School of Medicine, Elazig, Turkey.
Tissue Cell ; 76: 101752, 2022 Jun.
Article in En | MEDLINE | ID: mdl-35144124
ABSTRACT

INTRODUCTION:

BCC (Basal Cell Carcinoma) and trichoblastoma are skin tumors originating from the hair follicle. BCC is the most common non-melanoma skin cancer. Differential diagnosis of BCC from trichoblastoma, which is a common benign tumor in terms of histology, morphology, and immunohistochemistry, is not possible. The effects of adipokines on tumorigenesis have attracted attention. MATERIALS AND

METHODS:

By examining the effects of Asprosin and Meteorine like peptide (METRNL) on these tumors, it is aimed to reach new information in the differential diagnosis of BCC and trichoblastoma. Twenty normal healthy tissue, 17 basal cell carcinoma and 12 trichoblastoma samples were included in the study.

RESULTS:

Increased expression of Asprosin and METRNL was observed in tumor and stromal tissues in BCC. Although overexpression of METRNL was observed in the lesion area in trichoblastoma, no increase in Asprosin expression was observed. Asprosin and METRNL immunoreactivity were found to be statistically significantly higher in BCC samples compared to control and trichoblastoma.

CONCLUSION:

Asprosin and METRNL can be used in the diagnosis of BCC. METRNL can be used in the diagnosis of trichoblastoma. These biomarkers are helpful for differentiation between BCC and trichoblastoma.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Carcinoma, Basal Cell Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Tissue Cell Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Carcinoma, Basal Cell Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Tissue Cell Year: 2022 Document type: Article